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a  b  s  t  r  a  c  t
Regenerative  medicine  is  a distinct  major  advancement  in  medical  treatment  which  is based
on  the  principles  of stem  cell  technology  and  tissue  engineering  in order  to replace  or
regenerate  human  tissues  and  organs  and  restore  their  functions.  After  many  years  of  basic
research,  this  approach  is  beginning  to represent  a valuable  treatment  option  for  acute
injuries,  chronic  diseases  and  congenital  malformations.  Nevertheless,  it is  a little  knowneywords:
egenerative medicine
tem cells
iomaterials
rtiﬁcial organs
issue engineering
ﬁeld of  research.  The  purpose  of  this  review  is  to convey  the state  of  the  art in regenerative
medicine  in terms  of  historical  steps,  used  strategies  and  pressing  problems  to solve  in the
future.  This  review  represents  a good  starting  point  for more  in-depth  studies  and  personal
research projects.
©  2015  Published  by  Elsevier  Ltd.  on behalf  of  Saudi  Society  of  Microscopes.ontents
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. Historical background
Regenerative medicine (RM) implies the replacement or
egeneration of human cells, tissue or organs, to restore or
conference on Lake Como, in the attempt to describe
an emerging ﬁeld, which blent knowledge deriving from
different subjects: tissue engineering (TE), cell trans-
plantation, stem cell biology, biomechanics prosthetics,stablish normal function [1].
The term “regenerative medicine” is widely consid-
red to be coined by William Haseltine during a 1999
∗ Corresponding author. Tel.: +39 0264447605.
E-mail address: antonello.forgione@aimsacademy.org (A. Forgione).
http://dx.doi.org/10.1016/j.jmau.2015.05.002
213-879X/© 2015 Published by Elsevier Ltd. on behalf of Saudi Society of Microsnanotechnology, biochemistry [2]. Historically, this term
was found for the ﬁrst time in a 1992 paper by Leland
Kaiser, who  listed the technologies which would impact
the future of hospitals [3].
RM is considered a novel frontier of medical research,
but the idea of creating artiﬁcial organs is not so recent.
In 1938, a book, called “The culture of new organs”, was
copes.
scopy and Ultrastructure 3 (2015) 101–107
Table 1
A partial list of ﬁrsts in RM.
Year First
1968 First cell transplantation: bone marrow transplant [11]
1978 Discovery of stem cells in human cord blood [15]
1981 First in vitro stem cell line developed from mice [16]
1981 First engineered tissue transplantation: skin [17]
1996 Creation of the ﬁrst cloned animal: a sheep, named Dolly
[18]
1998 Isolation of human embryonic stem cells [19]
1999 First laboratory-grown organ: an artiﬁcial bladder
implanted in a patient suffering from myelomengicocele
[20]
2004 Implantation of ﬁrst engineered tubular organs (urine
conduits) [21]
2007 Discovery of stem cells derived from amniotic ﬂuid and
placenta [22]
2009 First solid organ engineered by recycling donor liver [23]102 G. Sampogna et al. / Journal of Micro
published and the authors were Alexis Carrell, a Nobel
Prize winner for his study on vascular anastomosis, and
Charles Lindbergh, the ﬁrst aviator to ﬂy across the Atlantic
alone. Wondering why his sister-in-law’s fatal heart con-
dition could not be repaired surgically, Lindbergh, despite
not being a professional, ended up working together with
Carrell at Rockefeller Institute for Medical Research during
the 1930s, where they created an artiﬁcial perfusion pump
allowing the perfusion of the organs outside the body dur-
ing surgery: their work was the basis for the development
of the artiﬁcial heart [4].
The regeneration of body parts is a rather common
phenomenon in nature; a salamander can regenerate an
amputated limb in several days [5]. Humans have this abil-
ity as well, but they lose it over the years: a severed ﬁngertip
can regenerate until 11 years of age [6]. The human regen-
eration potential was well-known also in ancient times, as
demonstrated by the myth of Prometheus: his liver was
eaten by an eagle during the day and it completely regen-
erated itself overnight.
During the last centuries medicine has gained many
successes: antibiotic therapy, anesthesia, sterilization, etc.
However, there are still many pathologies which can-
not be treated by preserving the affected organs, but
require the resection of lesions or the repair with autol-
ogous tissues or even the replacement with allografts
[7]. This is the three R’s paradigm in traditional surgery
with three solutions, all of which pose different prob-
lems.
When a surgeon resects an extensive part of small
bowel, leading to a malabsorption syndrome, called short
bowel syndrome, long-life total parenteral nutrition is
imposed, threatening patient’s life [8].
People suffering from high-pressure or poorly compli-
ant bladders may  need augmentation cystoplasty, which
is performed by using part of small bowel. Since gastroin-
testinal tissues adsorb solutes rather than excrete urine, the
repaired bladder is often complicated by increased mucous
production, infections, metabolic disturbances, urolithia-
sis, perforation and even cancer [9].
As for organ replacements, in 1954, the kidney was  the
ﬁrst organ to be substituted in a human, but between iden-
tical twins so that rejection did not arise [10]. Later, also cell
transplantation was achieved: an immunodeﬁcient patient
received his sibling’s bone marrow [11]. At ﬁrst, trans-
plants were relegated to research because of the adverse
immunological responses, but the advent of cyclosporine
in the 1980s transformed transplantations into life-saving
treatments, as the risk of rejection could be drastically
reduced. Nowadays, lifelong immunosuppression carries
many side effects, representing one of the two  big prob-
lems related to transplantations [12]. The other one is the
shortage of donors, not being able to meet the ever increas-
ing demand of organs [13]. Due to the progressively aging
population, transplantations will be increasingly needed to
replace end-stage diseased organs injured by age-related
diseases.All these issues are carrying with them economical and
social problems: while in 1941 there were 41 workers for
one retiree in the USA, now there are only three workers
for one retiree, so that the common invalidating chronicFig. 1. Strategies used in regenerative medicine. There are substantially
three approaches: cell-based therapy, use of engineered scaffolds and the
implantation of scaffolds seeded with cells.
diseases are bearing upon a small part of work-age citizens
[14].
Therefore, medicine is facing with pressing problems
which require an evolution of medical treatments and the
regeneration of damaged tissues, “the fourth R”, could revo-
lutionize modern medicine, offering the way  to cure, rather
than merely treat symptoms.
A partial list of the most relevant conquests in the his-
tory of regenerative medicine is reported in Table 1.
The later part of the article looks into the current strate-
gies used in RM and the associated shortcomings which
deter its liberal and convenient application in the clinical
setting on a daily basis.
2. Current strategies used in regenerative medicine
There are substantially three different approaches to
pursue the objective of RM (Fig. 1):
1. Cell-based therapy;
2. Use of either biological or synthetic materials to lead
repair processes and cell growth;
3. Implantation of scaffolds seeded with cells.2.1. Cell-based therapy
Humans have complex multicellular framework with
several types of cells specialized in particular functions.
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Table  2
Cell potency.
Totipotency The ability of a single cell to produce all cells
(potency possessed until 16-cell stage during
blastocyst phase)
Pluripotency The ability to differentiate into a cell of all
three germ layers (e.g. embryonic stem cells)
Multipotency Gene activation limits these cells to
differentiate into multiple, but limited cell
types (e.g. hematopoietic stem cells can
differentiate into all blood cells: erythrocytes,
lymphoid cells, neutrophils, platelets, etc.)
Oligopotency The ability to differentiate into limited cell
types (e.g. lymphoid stem cells become either
B cells or T cells)
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Fig. 2. Cell therapy bases on the injection of cells obtained by differ-
ent  methods. Adult primary cells are taken from patient and directly
implanted after expansion in vitro. Biopsied tissues contain adult stem
cells (ASCs) to expand, differentiate into a speciﬁc type and implant. Adult
skin cells may be reprogrammed through speciﬁc transcription factors in
order to obtain induced pluripotent stem cells. Embryonic stem cells are
derived from the inner cell mass of a blastocyst. At last, the amniotic ﬂuid
is  a potential source for stem cells (AFSCs). Read the text for a detailed
description. Abbreviations:  AFSCs, amniotic ﬂuid-derived stem cells; ASC,
adult stem cell.
Table 3
Derivates from germ layers.
Germ layer Derived tissues and organs
Ectoderm Epidermal tissues and nervous system
Mesoderm Bone, blood, cartilage, muscle, urogenitalUnipotency Ability to differentiate into one single cell type
(e.g. precursor cell)
owever, all cells descend from one unique cell, called
ygote. During development, cells differentiate progres-
ively and acquire more and more speciﬁc tasks, while they
ose their capacity for differentiating into other cells. The
bility to differentiate into other cell types is deﬁned as
cell potency” (Table 2).
Cell therapy consists of injecting novel and healthy cells
n pathologic tissues. It can rely either on already differen-
iated cells or on undifferentiated stem cells (Fig. 2), which
an differentiate depending on particular circumstances.
On the ﬁrst hand, the differentiated endogenous pri-
ary cells are collected by patient’s speciﬁc tissues with
he advantage of being ready to implant without any fur-
her manipulations, but expansion. However, it is difﬁcult
o get a considerable number of these cells in vitro, also
or organs (e.g. liver) with a great replication potential in
ivo, as the cells lose the usual microenvironment needed
o proliferate [24]. Therefore, these cells will be used less
nd less in the future, even if they are not correlated with
ejection and important inﬂammatory responses.
On the other hand, stem cells (SCs) can proliferate
xtensively, with the capacity of self-renewing while
hey maintain their undifferentiated state, until they are
nduced to differentiate into a speciﬁc cell type [25]. SCs can
e obtained in several ways. They are autologous if derived
rom patient, allogeneic if derived from a human donor and
enogeneic if derived from another animal.
Adult stem cells (ASCs) had been isolated from nearly all
uman adult body tissues, where their goal is to restore
riginal tissue function after minor injuries [26]. Among
hese cells, a preeminent role is played by the bone
arrow-derived mesenchymal stem cells (MSCs), as they
ad been studied deeply. Using different culture protocols,
hey have been shown to be able to differentiate into many
inds of cells, useful to treat bone, cartilage, nervous, mus-
le, cardiovascular, blood, gastrointestinal diseases [27].
By aspirating the inner cell mass from an embryo during
he blastocyst stage (5 days post fertilization), we can get
mbryonic stem cells (ESCs), which can proliferate exten-
ively while maintaining their pluripotent state until they
re induced to differentiate into one kind of cells from all
he three embryogenic germ layers (Table 3) [28]. Human
SCs can be derived from the surplus of embryos gener-
ted during in vitro fertilization. Besides the huge potential,system, serous membranes
Endoderm GI tract, airways
there are several issues with the use of ESCs which cannot
be ignored:
- Rejection: they are allogeneic, but immune responses can
be avoided with some new developing technologies, like
therapeutic cloning and adult cell reprogramming;
- Need for feeder cells for trophic support: ﬁrst time feeder
cells were used in mouse ﬁbroblasts, correlated with the
risk of xeno-contamination [29];
- Carcinogenesis: ESCs can develop into teratomas [30];
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Table 4
Advantages and disadvantages of cell types used in RM.
Cell type Advantages Disadvantages
Differentiated endogenous
primary cells
No tissue rejection
Reduced inﬂammatory response
Difﬁcult expansion because of
in vitro short lifespan
Difﬁculty in getting healthy cells in
diseased organs
Adult stem cells (ASCs) No tissue rejection
No ethical problems
No tumors
Easy isolation
In some cases easy access (e.g. apheresis and subcutaneous fat)
Low number in each tissue
Difﬁcult in vitro expansion without
differentiation
Embryonic stem cells
(ESCs)
Unlimited ability to self-renew
Potential to differentiate into many specialized cells from all the
three germ layers
Ethical and political problems
Tumorigenity
Need for feeder cell layers (risk of
xeno-contamination when mouse
ﬁbroblasts are used)
Induced pluripotent stem
cells (iPSCs)
Similar as ESCs
Easier generation than ESCs
No ethical problems
Tumorigenity
Amniotic ﬂuid-derived
stem cells (AFSCs)
Great ability to proliferate without feeder cells
No  tumorigenic
No ethical problems
Possibility of preservation as lifelong autologous stem cells
together with other perinatal stem cells (umbilical cord placenta
tem cell
 by amn
Further research is needed (being
the latest discovery)and amnion membrane-derived s
Possibility of ante-natal collection
villous sampling
- Ethical and moral issues: they represent a notable source
of debate, as their source is an embryo, whose develop-
ment is interrupted by the aspiration.
The ﬁrst recipient of these cells was a young man, who
had a spinal cord injury in a car accident: he received the
injection of oligodendrocytes obtained from ESCs [31].
Another strategy to obtain ESCs is the so-called ther-
apeutic cloning or somatic cell nuclear transfer (SCNT),
which is based on the transfer of a somatic cell nucleus
into an oocyte. In this way, early stage embryos are cul-
tured to produce ESCs with the potential to become almost
any adult cell types [32]. Besides being a source for RM,
this technique is also the basis for cloning animals, like the
famous sheep, called Dolly [18]. Through this technology,
pathologic cell lines can be obtained to study the effects of
some molecules in cells with speciﬁc diseases.
Autologous stem cells can also be obtained through a
reprogramming of adult cells to get induced pluripotent
stem cells (iPSCs). They have the same cell potency as ESCs,
so they could replace the controversial use of ESCs. The
generation of iPSCs was ﬁrstly achieved by introducing a
series of transcription factors into murine ﬁbroblasts: the
ﬁrsts were OCT3/4, SOX2, KLF4 and c-MYC [33]. The lat-
ter, c-MYC, is an oncogene and could give rise to tumors,
so it had been replaced successfully, according to differ-
ent reports, using OCT4, SOX2, NANOG and LIN28 [34].
Unfortunately, in this way the process took longer and was
not as efﬁcient as the other protocol. Originally, the deliv-
ery of these transcription factors was achieved through
the use of retro- and lentiviral constructs, but, since this
strategy could provoke insertional mutagenesis and onco-
gene activation, it should be substituted by non-viral-based
methods or by the adenovirus-based transient transfection
without genomic integration [35]. Recently, iPSCs weres)
iocentesis or chorionic
obtained in mice in vivo without the use of a Petri’s dish
[36].
Another important feature of iPSCs is their use for the
generation of disease-speciﬁc lines (for example, affected
by Parkinson’s disease, Alzheimer’s disease, diabetes melli-
tus type I) to study disease mechanisms and drug screening
[37].
A human clinical trial with iPSCs is being conducted at
Japanese RIKEN Center for Developmental Biology [38]. The
ﬁrst recipient was  a 70-year-old woman affected by exuda-
tive age-related macular degeneration (AMD), whose skin
cells were taken and induced to differentiate into retinal
pigment epithelium (RPE) cells, which were used to create
a small monolayered RPE sheet to implant into the patient’s
eye, without any biomaterials.
Lastly, scientists can obtain SCs from amniotic ﬂuid
and placenta by amniocentesis or chorionic villous samp-
ling in the developing fetus or from the placenta at birth,
the so-called amniotic ﬂuid-derived stem cells (AFSCs)
[22]. These cells are multipotent and do not develop neo-
plasms. A range of possible clinical applications has been
described in the literature. For example, AFSCs from cell
banks can represent a lifelong autologous source for heart-
valve replacements [39]. Since they are very promising,
they have been studied deeply in the recent past, but no
human clinical trials have been performed yet.
All the advantages and disadvantages related to the dif-
ferent cell types are summarized in Table 4.
2.2. Biomaterials
Tissues generally consist of cells and extracellular
matrix (ECM). Biomaterials usually serve as ECM, giving
both structural and functional support. During the last few
years, ECM has been shown to play a key role in many dif-
ferent functions, such as gene expression, survival, death,
G. Sampogna et al. / Journal of Microscopy an
Table  5
Examples of biomaterials used in RM.
Origin Examples
Natural materials Collagen, ﬁbrin, chitosan, dextran, alginate,
gelatin, cellulose, hyaluronic acid (HA), silk
ﬁbroin
Acellular tissue
matrix
Bladder acellular matrix (BAM), small
intestinal submucosa (SIS), bowel acellular
tissue matrix (ATM), bovine pericardium
(BPV), human placental membrane (HPM)
Synthetic polymers Polyglycolic acid (PGA), polylactic acid (PLA),
poly(lactic-co-glycolic) acid (PLGA),
polycaprolactone (PCL),
poly(copralactone-co-ethyl ethylene posphate)
(PCLEEP), polydioxane (PDS), polyethylene
glycol (PGE),
poly-N-(2-hydroxyethyl)metacrylamide
p
t
b
m
o
a
a
d
l
p
n
n
m
h
s
p
b
m
b
w
s
d
p
u
F
(
d
S
C(PHEMA),
poly-N-(2-hydroxypropyl)methacrylamide
(PHPMA)
roliferation, migration, differentiation. Therefore, all of
hem should be reproduced by biomaterials enriched with
ioactive factors, such as growth factors and cytokines. The
aterials used in RM (Table 5) can be classiﬁed as natural
r synthetic with different advantages and disadvantages.
Synthetic materials can be identically reproduced on
 large scale with speciﬁc properties of microstructure
nd degradation rate. However, they have the important
rawback of lacking of biologic recognition. Neverthe-
ess, different research groups are trying to solve this
roblem by incorporating the molecules to help the recog-
ition of synthetic scaffolds. By assembling electrospun
anoﬁbers and self-assembling peptides with functional
otifs (Fig. 3), Gelain et al. created neural prosthetics which
ad shown to lead nerve regeneration in rats with chronic
pinal cord injury [40].
On the other hand, natural materials can be integrated
erfectly. They can be furnished by other living organisms,
ut in these cases they present cellular components which
ay induce an immune response. The latter can be avoided
y making use of detergents (e.g. trypsin/TritonX-100)
hich leave only ECM, creating the so-called acellular tis-
ue matrices [41]. Unlike synthetic ones, both naturally
erived materials and acellular tissue matrices can not be
roduced easily in large quantities according to good man-
facturing practice.
ig. 3. Schematic models of the self-assembling peptide used by Gelain et al., R
different colored bars) in order to design different peptides. A schematic model o
ifferent biological functions is shown right.
ource: Gelain F, Bottai D, Vescovi A, Zhang S. Designer Self-Assembling Peptid
ultures. PLoS One. 2006 Dec 27;1:e119.d Ultrastructure 3 (2015) 101–107 105
The most used natural biomaterial is probably the
hyaluronic acid, which is a common anti-aging product
in skin-care products and injectable facial ﬁllers. As for
sample acellular tissue matrix applications, Portis et al.
demonstrated the feasibility of laparoscopic bladder aug-
mentation in minipigs using porcine bowel acellular tissue
matrix and porcine small intestinal submucosa [42].
The ideal biomaterial should be biocompatible and
biodegradable at the same rate as regeneration pro-
cess without leaving toxic end-products, interfering with
regeneration process and causing inﬂammation and/or
obstruction [43].
Another important feature is porosity, which allows
the exchange of nutrients and wastes. This property is
extremely difﬁcult to be achieved successfully and 3D bio-
printers seem to be the perfect solution of this problem.
The research group guided by Shaochen Chen bioprinted
a 3-D liver-like device to detoxify blood, by encapsulating
functional nanoparticles in a biocompatible hydrogel [44].
Thanks to a technology, called dynamic optical projection
stereolithography, complex 3D microstructures, like blood
vessels, can be printed within few seconds. Without vas-
culature printing, essential for distributing nutrients and
oxygen, tissue-engineered organs, such as liver or kidney,
are useless in clinical practice. The biofabrication technique
grounds on a photo-induced solidiﬁcation process, which
uses soft biocompatible hydrogels containing living cells
and forms one layer of solid structure at a time, but in a
continuous fashion, by shining light on a selected area of a
solution containing photo-sensitive biopolymers and cells
[45]. Other current 3D biofabrication techniques, such as
two-photon photopolymerization, can take hours to fab-
ricate a 3D part. At last, Organovo is a medical start-up
intending to deliver bioprinted organs, like liver, for sur-
gical therapy and transplantation [46].
2.3. Implantation of scaffolds seeded with cells
This approach is a combination of the previous two
strategies.In 2006, Atala et al. reported autologous engineered
bladder constructs could be used in patients suffering
from myelomeningocele needing augmentation cysto-
plasty [20]. The synthetic scaffold was made up of collagen
ADA16 (blue bars), extended though several different functional motifs
f a self-assembling nanoﬁber scaffold with combinatorial motifs carrying
e Nanoﬁber Scaffolds for Adult Mouse Neural Stem Cell 3-Dimensional
scopy an
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and PGA and seeded with patient’s urothelial and smooth
muscle cells, respectively on the endoluminal and ablu-
minal side. These cells were obtained through a patient’s
biopsy and expanded in vitro before scaffold seeding.
Another example is the realization of a bioartiﬁcial liver
obtained through the decellularization process [23]. The
latter consists of eliminating all liver cells preserving the
structural and functional characteristics of the vascular
network, which allows the organ perfusion. Later, adult
hepatocytes recolonize liver matrix and support physiolog-
ical functions, like albumin excretion and urea synthesis.
The liver grafts obtained in this way were successfully
transplanted into mice, paving the way for a new approach
to the treatment of end-stage liver diseases.
3. Conclusions
RM opened new avenues for curing patients with
difﬁcult-to-treat diseases and physically impaired tissues.
Despite many successes, RM is still unfamiliar to many sci-
entists and clinicians. This poses a great limit, as tissue
engineering and regenerative medicine could overcome
the unsolvable problems of the current medical treatments.
In order to resort to RM in the clinical setting on a daily
basis, it is mandatory to obtain important ﬁnancial invest-
ments from different sources including governments and
industries that are oriented toward research and medi-
cal innovation. There is a considerable need for long-term
vision and support for RM to accelerate the development
of novel therapies and to promote the stability of collabo-
rations around the world.
In addition to the ﬁnancial and technical concerns,
process development is a signiﬁcant hurdle to manage
with and it includes intellectual property, manufacturing,
and logistical concerns. Cell therapy and tissue engineer-
ing have the potential to revolutionize patients’ care. But
in order to materialize this concept, ideas generated in
the laboratory need to be taken through process devel-
opment and transformed into widespread commercial
products. Licensing, legal support, logistics, supervision
at the governmental level, unexpected failures, and team
management play a pivotal role.
Since RM is a cross-sectional area of research, a multidis-
ciplinary team, including doctors, biologists, bioengineers,
chemists, and surgeons, is required to initiate and master
the key steps involved in cell therapy and tissue engineer-
ing. This necessitates the need for training courses of cell
culture, stem cell technology, tissue engineering and exper-
imental surgery.
The crucial point of this revolution is transforming the
current numerous scientiﬁc discoveries into novel and
viable therapies: from bench to bedside.
Conﬂict of interestNone declared.
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